News from the Memory and Aging Program at Butler Hospital
February 25, 2021
In this recent Neurology Live article, Dr. Stephen Salloway, Director of Neurology and of the Memory and Aging Program at Butler Hospital and Professor, Warren Alpert Medical School of Brown University, shared some important insights on the potential impact of the drug, if it is approved.
My take is that it would open a new modern treatment era for AD. It would just be the beginning—a stepping stone, rather than the final breakthrough. There was a really good quote the other day, from a colleague of mine, who said, “In order to get the best-in-class drug, we must have the first-in-class drug.” That’s how I see this.
